September 15, 2023
To whom it may concern:

Company Name:Corporate
Representative:
Contact:

TOHO HOLDINGS CO., LTD.
Atsushi Udoh, RepresentativeDirector, CEO(Prime Market of Tokyo Stock
Exchange Securities Code: 8129)
Makoto Kawamura, Corporate Officer
and General Manager, Corporate
Communications and Investor
Relations Division(TEL: 81-3-6838-2803)

Conclusion of Capital and Business Alliance with MICIN, Inc.
TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh; hereinafter “TOHOHOLDINGS”) announces that it has agreed to enter into a capital and business alliance with MICIN, Inc. (Headquarters:Tokyo; Representative CEO: Seigo Hara; hereinafter “MICIN”), as described below.
1. Reason for the business alliance
TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceuticalwholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer
support systems under the corporate slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively
promotes initiatives for regional medical collaboration, nursing and home care.
Toward the realization of its vision, “FOR ALL TO LIVE OUT THEIR LIVES WITH DIGNITY”, MICIN is engaged in
Telehealth business (Telemedicine service “curon”, etc.), Decentralized clinical trials business (DCT (*1) support system“MiROHA”, etc.), Digital therapeutics (*2) business, Insurance business, etc. aimed at providing diagnosis, treatment, andsecurity tailored to the individual’s needs.
In its Medium-term Management Plan 2023-2025 “Create the Next Generation”, TOHO HOLDINGS has set “Investmentfor growth and improvement of profitability” as one of its basic policies and is determined to push ahead with concretemeasures such as “Evolution of customer support business” by actively promoting alliances and DX. The capital and businessalliance is expected to generate synergies between TOHO HOLDINGS’ pharmaceutical wholesaling, dispensing pharmacy,
customer support system, and other businesses and MICIN’s businesses, and will contribute to solving various issues in thehealthcare field and enhance corporate value over the medium to long term.
*1 Decentralized Clinical Trial. To conduct a clinical trial by combining data collection at the patient’s home or at a partner medicalinstitution, etc., without necessarily depending on a visit to the study site.
*2 Software-assisted therapeutic interventions based on medical evidence that support not only disease management, but also disease
prevention and treatment.

2. Overview of MICIN(1) Company name:(2) Location:(3) Representative:(4) Established:(5) Business content:(6) Capital:

MICIN, Inc.
12F, TOKIWA BRIDGE, 2-7-1, Otemachi, Chiyoda-ku, Tokyo, 100-0004
Seigo Hara, Representative CEO
November 26, 2015
Telehealth Business, Decentralized Clinical Trials Business, Digital therapeutics Business,
Insurance Business, etc.
100 million yen

3. Forward looking outlook
The impact of this business alliance on the Company’s business performance is expected to be minimal, but the Company
will disclose any impact promptly if it becomes necessary to do so in the future.